Lyell Immunopharma, Inc. / A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Therapy Product Candidate, Versus Investigator?s Choice of CD19 CAR T-Cell Therapy in Patients with Rela